Tim Van Hauwermeiren, argenx CEO
Argenx purchases $100M+ FDA priority review voucher from bluebird bio
Argenx’s Vyvgart is due for a speedy review at the FDA, thanks to a $102 million priority review voucher (PRV).
The Netherland-based biotech picked up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
